AZD1222/ChAdOx1 NCoV-19 Vaccination Induces a Polyfunctional Spike Protein-specific T1 Response with a Diverse TCR Repertoire

Overview

Journal Sci Transl Med

Specialties General Medicine
Science

Date 2021 Sep 30

PMID 34591596

Citations 70

Authors

Phillip A Swanson 2nd

Marcelino Padilla

Wesley Hoyland

Kelly McGlinchey

Paul A Fields

Sagida Bibi

Saul N Faust

Adrian B McDermott

Teresa Lambe

Andrew J Pollard

Nicholas M Durham

Elizabeth J Kelly

Affiliations

Soon will be listed here.

Abstract

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in clinical trials and real-world studies. We characterized CD4 and CD8 T cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells from 296 unique vaccine recipients aged 18 to 85 years who enrolled in the phase 2/3 COV002 trial. Total spike protein–specific CD4 T cell helper type 1 (T1) and CD8 T cell responses were increased in AZD1222-vaccinated adults of all ages after two doses of AZD1222. CD4 T2 responses after AZD1222 vaccination were not detected. Furthermore, AZD1222-specific T1 and CD8 T cells both displayed a high degree of polyfunctionality in all adult age groups. T cell receptor β (TCRβ) sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for both AZD1222-induced CD4 and CD8 T cell responses. Overall, AZD1222 vaccination induced a polyfunctional T1-dominated T cell response, with broad CD4 and CD8 T cell coverage across the SARS-CoV-2 spike protein.

Citing Articles

Contrasting Effects of SARS-CoV-2 Vaccination vs. Infection on Antibody and TCR Repertoires.

Braun J, Hill E, Contreras E, Yasuda M, Morgan A, Ditelberg S bioRxiv. 2025; .

PMID: 39829775 PMC: 11741250. DOI: 10.1101/2023.09.08.556703.

COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from -endemic villages in Mayuge District, Uganda: a cross-sectional study.

Niu M, Mu Y, Adriko M, Candia R, Jones M, McManus D Front Public Health. 2024; 12:1437063.

PMID: 39624416 PMC: 11609215. DOI: 10.3389/fpubh.2024.1437063.

Impact of Immunosenescence on Vaccine Immune Responses and Countermeasures.

Chen L, Shao C, Li J, Zhu F Vaccines (Basel). 2024; 12(11).

PMID: 39591191 PMC: 11598585. DOI: 10.3390/vaccines12111289.

The characteristics of TCR CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccine recipients.

Zhou D, Luo Y, Ma Q, Xu Y, Yao X Virulence. 2024; 15(1):2421987.

PMID: 39468707 PMC: 11540089. DOI: 10.1080/21505594.2024.2421987.

Wuhan Sequence-Based Recombinant Antigens Expressed in Elicit Antibodies Capable of Binding with Omicron S-Protein.

Evtushenko E, Ryabchevskaya E, Kovalenko A, Granovskiy D, Arkhipenko M, Vasiliev Y Int J Mol Sci. 2024; 25(16).

PMID: 39201702 PMC: 11354337. DOI: 10.3390/ijms25169016.

References

FULGINITI V, Eller J, DOWNIE A, KEMPE C . Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA. 1967; 202(12):1075-80. DOI: 10.1001/jama.202.12.1075. View

Tan A, Linster M, Tan C, Bert N, Chia W, Kunasegaran K . Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021; 34(6):108728. PMC: 7826084. DOI: 10.1016/j.celrep.2021.108728. View

Gallais F, Velay A, Nazon C, Wendling M, Partisani M, Sibilia J . Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis. 2020; 27(1). PMC: 7774579. DOI: 10.3201/eid2701.203611. View

Vasileiou E, Simpson C, Shi T, Kerr S, Agrawal U, Akbari A . Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021; 397(10285):1646-1657. PMC: 8064669. DOI: 10.1016/S0140-6736(21)00677-2. View

Agrawal A, Tao X, Algaissi A, Garron T, Narayanan K, Peng B . Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016; 12(9):2351-6. PMC: 5027702. DOI: 10.1080/21645515.2016.1177688. View

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088. PMC: 8116636. DOI: 10.1136/bmj.n1088. View

Emary K, Golubchik T, Aley P, Ariani C, Angus B, Bibi S . Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021; 397(10282):1351-1362. PMC: 8009612. DOI: 10.1016/S0140-6736(21)00628-0. View

Klinger M, Pepin F, Wilkins J, Asbury T, Wittkop T, Zheng J . Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing. PLoS One. 2015; 10(10):e0141561. PMC: 4624875. DOI: 10.1371/journal.pone.0141561. View

Juno J, Tan H, Lee W, Reynaldi A, Kelly H, Wragg K . Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; 26(9):1428-1434. DOI: 10.1038/s41591-020-0995-0. View

10.

Monaco G, Chen H, Poidinger M, Chen J, de Magalhaes J, Larbi A . flowAI: automatic and interactive anomaly discerning tools for flow cytometry data. Bioinformatics. 2016; 32(16):2473-80. DOI: 10.1093/bioinformatics/btw191. View

11.

Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R . T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; 27(2):270-278. DOI: 10.1038/s41591-020-01194-5. View

12.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

13.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

14.

Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A . Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012; 4(115):115ra1. PMC: 3627207. DOI: 10.1126/scitranslmed.3003155. View

15.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

16.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J . Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021; 592(7854):438-443. DOI: 10.1038/s41586-021-03402-9. View

17.

Addetia A, Crawford K, Dingens A, Zhu H, Roychoudhury P, Huang M . Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020; 58(11). PMC: 7587101. DOI: 10.1128/JCM.02107-20. View

18.

Robins H, Campregher P, Srivastava S, Wacher A, Turtle C, Kahsai O . Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009; 114(19):4099-107. PMC: 2774550. DOI: 10.1182/blood-2009-04-217604. View

19.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

20.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View